Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy by Gutman, Julie et al.
REVIEW Open Access
Combination of probenecid-sulphadoxine-
pyrimethamine for intermittent preventive
treatment in pregnancy
Julie Gutman
1*, S Patrick Kachur
1, Laurence Slutsker
2, Alexis Nzila
3 and Theonest Mutabingwa
4
Abstract
The antifolate sulphadoxine-pyrimethamine (SP) has been used in the intermittent prevention of malaria in
pregnancy (IPTp). SP is an ideal choice for IPTp, however, as resistance of Plasmodium falciparum to SP increases,
data are accumulating that SP may no longer provide benefit in areas of high-level resistance. Probenecid was
initially used as an adjunctive therapy to increase the blood concentration of penicillin; it has since been used to
augment concentrations of other drugs, including antifolates. The addition of probenecid has been shown to
increase the treatment efficacy of SP against malaria, suggesting that the combination of probenecid plus SP may
prolong the useful lifespan of SP as an effective agent for IPTp. Here, the literature on the pharmacokinetics,
adverse reactions, interactions and available data on the use of these drugs in pregnancy is reviewed, and the
possible utility of an SP-probenecid combination is discussed. This article concludes by calling for further research
into this potentially useful combination.
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Background
Decreasing efficacy of sulphadoxine-pyrimethamine for
intermittent prevention of malaria in pregnancy
T h ea n t i f o l a t es u l p h a d o x i n e-pyrimethamine (SP) has
been used in the intermittent prevention and treatment
of malaria in pregnancy; in addition, it has been explored
for intermittent preventive treatment (IPT) in infants and
children [1-7]. SP is an ideal choice for intermittent pre-
ventive treatment in pregnancy (IPTp), as it is effective as
a single dose given two to three times in pregnancy, with
an interval of at least one month between doses. Data
from Mali suggest that three doses are significantly more
effective than two doses [8]. Resistance of Plasmodium
falciparum to SP has been increasing, and its use is no
longer recommended for treatment of malaria in Africa
[9-11]. In some areas where SP is no longer an effective
malaria therapy, IPTp with SP has been shown to be ben-
eficial to HIV-uninfected pregnant women, possibly as a
result of their pre-existing immunity [1]. Of concern,
however, is a recent report from Muheza, an area of
Tanzania with high level SP resistance, suggesting that its
use for IPTp may exacerbate resistance [12]. In that
study, SP-IPTp was associated with a 5.4% increase (p =
0.003) in the prevalence of parasitaemia in women who
reported SP-IPTp use compared to those who did not. In
addition, women who reported SP-IPTp use had both a
higher prevalence of placental inflammation by histo-
pathology and higher intensity of inflammation than
women who did not report using SP-IPTp [12]. A subse-
quent study from the same area showed the lack of bene-
ficial pregnancy outcomes from SP-IPTp [13]. Data from
Malawi also show that the effectiveness of SP-IPTp has
been decreasing over time and no longer appears to pro-
vide any benefit [14]. In view of these findings, it is criti-
cal to search for new agents for IPTp; mefloquine or
azithromycin-based combinations (including azithromy-
cin plus chloroquine) currently appear most promising
[15]. While searching for alternatives to SP-IPTp, data
from in vitro experiments have shown that probenecid
can increase the activity of the anti-malarial antifolates
[16,17]. Furthermore, malaria treatment studies in Niger-
ian children have shown that the addition of probenecid
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any medium, provided the original work is properly cited.increases the treatment efficacy of SP [18,19]. Implicitly,
the combination of probenecid plus SP may prolong the
useful lifespan of SP as an effective agent for IPTp.
Mechanism of action and development of resistance to
SP
Sulphadoxine and pyrimethamine act synergistically to
inhibit two steps in the folate synthesis pathway. Sulpha-
doxine inhibits the enzyme dihydropteroate synthetase
(dhps) while pyrimethamine inhibits the enzyme dihydro-
folate reductase (dhfr). Resistance develops in a step-wise
manner due to a combination of mutations in these genes,
with increasing numbers of mutations conferring increas-
ing levels of resistance [20]. This results in an increased
minimal inhibitory concentration (MIC), which translates
to a decreased duration of prophylaxis because as drug
levels fall, they reach the point at which they no longer
suppress parasite replication sooner (Figure 1) [21]. The
presence of the “quintuple mutant” consisting of the dhfr
triple mutant (point mutations causing a Ser ® Asn
change at position 108, Asn ® Ile at codon 51, and Cys ®
A r ga tc o d o n5 9 )a n dt h edhps double mutant (due to
point mutations which convert Ala ® Gly at codon 437
and Lys ® Glu at codon 540) has been most strongly
associated with treatment failure [22], although host
immunity still plays a significant role in determining drug
efficacy [23]. Although theoretically, increasing the dose of
SP could potentially overcome resistance to some degree,
modelling suggests that increasing the dose of SP dose will
only have a marginal benefit since highly resistant para-
sites will not be efficiently cleared by in vivo drug levels
achievable within safety margins [24]. Furthermore, data
in pregnant women indicate that there is significant
variability in the effect of pregnancy on the disposition of
SP, thus it was concluded that it is not possible to recom-
mend an adjustment to the dose of SP to increase its effi-
cacy [25].
Rationale for use of probenecid
Probenecid was developed in 1950 to inhibit the renal
tubular secretion of penicillin, increasing the blood con-
centration of the drug and decreasing the required dose
[26,27]. Since its introduction, it has been found to inhi-
bit the tubular secretion of other weak organic acids,
such as p-aminohippuric acid, salicylic acid and uric
acid, as well as other antibiotics (including cephalospor-
ins), and anti-retrovirals (including oseltamavir and
zidovudine). This characteristic of probenecid allows for
decreased doses of medications to be used, thus limiting
toxicity, especially with nephrotoxic agents [27-30]. Pro-
benecid has been widely used as an uricosuric agent in
the treatment of gout [26], and has a long history of use
without serious toxicity [31]. It is widely available and
inexpensive, costing approximately US$1 per 500 mg
tablet.
Probenecid is a substrate for multi-drug resistance-
associated protein (MRP) and the uric acid transporter
[32] and is an inhibitor of both organic anion transpor-
ters 1 and 3 (OAT1 and OAT3) [33-35]. Probenecid
increases plasma concentrations of the antifolate metho-
trexate by inhibiting drug efflux mediated by the MRP
family of ATP-binding cassette transporters while at the
same time inhibiting folate uptake [36]. This has been
shown to reverse some forms of methotrexate resis-
tance, and can increase the anti-cancer efficacy of anti-
folate drugs (methotrexate analogs) [36,37].
Figure 1 Hypothetical parasite burden profiles during pregnancy with SP IPT in a high-transmission setting. Entomological inoculation
rate is about 50 infectious bites per person per year. Note that many infections self-cure (each infection is depicted as a green line). The
hatched bars represent the duration of “suppressive prophylactic activity”, and the solid bars represent the period during which parasite
multiplication is suppressed (i.e. levels exceed the in vivo MIC). The horizontal dotted line at 10
8 parasites represents the level at which malaria
can be detected on a blood film. (A) represents a drug-sensitive area; (B) represents a moderately resistant area. Reproduced from: White NJ
(2005) Intermittent Presumptive Treatment for Malaria. PLoS Med 2(1): e3. doi:10.1371/journal.pmed.0020003
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clearly demonstrated that the addition of folate deriva-
tives decreases the activity of antifolate drugs, both in
vitro and in vivo [38-40]. Likewise, the lowering of folate
concentration in vivo enhances the activity of antifolate
anti-malarial agents [41]. This, taken together with the
data from the studies of methotrexate, suggests that pro-
benecid may be able to increase the efficacy of antifo-
lates against resistant Plasmodium parasites by
increasing the concentration of drug and limiting the
uptake of folate. This has been demonstrated in vitro
for the antifolates sulphadoxine, dapsone, pyrimetha-
mine, and chlorcycloguanil [17]. In the presence of clini-
cally achievable probenecid concentrations (50 μMo r
14.268 mcg/ml), the activity of these antifolates was sig-
nificantly increased. Increased activity ranged from two-
to seven-fold, and in the case of resistant parasite iso-
lates, reduced half maximal inhibitory concentrations
(IC50) to levels seen in drug sensitive isolates [17]. These
improvements in drug susceptibility correlated with
reduced folate uptake in the presence of probenecid
[17]. Probenecid has also been shown to reverse chloro-
quine resistance and increase piperaquine activity in
vitro [17,42].
Probenecid has been shown to increase the efficacy of
SP for the treatment of malaria in clinical trials in Nigerian
children in an area with approximately 25% resistance to
SP. In a study of 151 children under the age of 12 years,
Sowunmi et al. showed that the addition of approximately
20-25 mg/kg/d of probenecid for three-days to standard
SP dosing increased the efficacy of SP, as measured by the
parasitological cure rate at day 14, compared to children
who received SP alone (96.2% vs 83.5%, p = 0.02, n = 78
and 73, respectively) [19]. Although the cure rate in the
SP-probenecid group remained higher at day 28, this was
no longer statistically significant (79.4% vs 72.6%, p = 0.4)
[19]. The combination of SP-probenecid was well tolerated
in this small study and had no significant side effects [19].
Similar findings were reported from the same study popu-
lation, with a 14-day cure rate of 100% in the SP-probene-
cid arm (n = 5) compared to 88% in the SP arm (n = 25)
in one study and 94.8% (n = 39) compared to 76.4% (n =
34, p = 0.02) in another [18,43].
Although probenecid has been in use for over half a
century, and has been recommended as part of the
treatment of gonorrhea in pregnancy, very little clinical
data exist on its safety in pregnancy. Furthermore, no
clinical studies have been done on the pharmacokinetics
of probenecid in pregnancy. Available evidence suggests
that probenecid may potentiate the effect of SP and thus
prolong its use for IPTp. However, data from pregnant
women are needed to explore this potential. This review
presents available data and highlights the knowledge
gaps surrounding potential use of SP-probenecid combi-
nation as an effective agent for IPTp.
Pharmacokinetics
Probenecid
Probenecid is packaged as 500 mg tablets. It is a weak acid
(pKa 3.7) [44], and its oral bioavailability is > 90% [45]. In
healthy adults, probenecid is 85-95% bound to plasma
albumin and has a small apparent volume of distribution
of 0.003-0.014 L/kg [44,46]. The maximum adult dose of
probenecid is 3 g, and a single oral dose of 2 g (approxi-
mate 25 mg/Kg) yields peak plasma concentrations of
150-200 mcg/mL within four hours; concentrations above
50 mcg/mL are sustained for eight hours [31,47]. Follow-
ing a 2 g dose, the half-life is 4-17 h; the half-life is dose-
dependent, decreasing as the dose decreases to 500 mg
[31]. Probenecid is metabolized in the liver via oxidation
and glucuronidation and is primarily excreted in the urine
(75-85%) [27]. No dosage adjustment is necessary for
patients with mild renal failure (glomerular filtration rate
greater than 50 mL/min); probenecid is not effective in
severe renal failure and should be avoided [48,49]. No data
are available on the pharmacokinetics of probenecid in
pregnant women.
Sulphadoxine-pyrimethamine (SP)
SP is packaged as a fixed dose combination containing 500
mg sulphadoxine and 25 mg pyrimethamine and costs
approximately US$1 per treatment (adult dosage is three
tablets). In the non-pregnant population, both sulphadox-
ine and pyrimethamine have an oral bioavailability of
> 90%, and are 85-90% protein bound [25]. The volume of
distribution for sulphadoxine and pyrimethamine is 0.14
L/kg and 2.3 L/kg, respectively [50]. Oral administration
of one tablet yields peak plasma levels of approximately
0.2 mg/L for pyrimethamine and approximately 60 mg/L
for sulphadoxine at approximately four hours [50]. Both
compounds have a very long half-life; the half-life of sul-
phadoxine is approximately 169 h (range 100-230 h),
while that of pyrimethamine is approximately 111 h (range
54-148 h) [51]. Sulphadoxine is metabolized via glucuroni-
dation and excreted primarily in urine, while pyrimetha-
mine is metabolized to several unidentified metabolites
but also excreted primarily in the urine [25,52].
Several studies have examined the pharmacokinetics of
SP in pregnant women. All examined the standard dose
f o rI P T po ft h r e et a b l e t s( 1 5 0 0m go fs u l p h a d o x i n ea n d
75 mg of pyrimethamine). Nyunt et al. studied women
in four African countries both during pregnancy and six
to eight weeks post-partum, and found that, at Day 7
following administration of SP, there was an increased
blood concentration of pyrimethamine, with an area
under the curve (AUC) of 1,906 ng·day/ml during preg-
nancy vs 849 ng·day/ml postpartum, with geometric
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nancy and postpartum period 1.38 (1.22-1.56), p-value <
0.0001. In addition, they found decreased concentration
of sulphadoxine with an AUC of 877 μg·day/ml during
pregnancy versus 884 μg·day/ml postpartum, with geo-
metric mean ratio of pharmacokinetic values between
pregnancy and postpartum period 0.88 (0.80-0.96),
p-value = 0.004, also on Day 7. However, there was sig-
nificant variation in the exact pharmacokinetic para-
meters among the different study sites [25]. Findings
from a study done in Kisumu, Kenya by Green et al.,
looking at levels of SP during pregnancy compared to
eight-12 weeks post-partum, found similar results for
sulphadoxine [53]. However, pyrimethamine pharmaco-
kinetics were not significantly different in pregnant vs
non-pregnant women [53]. In a third study conducted
in Papua New Guinea where pregnant women were
matched to non-pregnant controls, plasma concentra-
tions of both sulphadoxine and pyrimethamine were
found to be lower in the pregnant women compared to
the non-pregnant controls (AUC of 22,315 vs 33,284
mg·h/l for sulphadoxine and 72,115 vs 106,065 μg·h/l for
pyrimethamine; p-value < 0.001 for both) [54]. These
varying results may be due to genetic differences in the
women that contribute to differential drug metabolism,
as well as to differences in body weight.
There are no data on how the combination of probe-
necid, sulphadoxine, and pyrimethamine affects pharma-
cokinetics or pharmacodynamics of the individual drugs.
Further studies are needed to define these effects and to
determine optimal dosing regimens. Given the signifi-
cant differences in the half lives of SP and probenecid,
there is also a need to optimize the probenecid regimen
to maximize efficacy of SP while minimizing the fre-
quency of administration to facilitate adequate compli-
ance and adherence.
Adverse events
Probenecid
Adverse reactions with probenecid are quite rare, occur-
ring in approximately 0.1-0.3% of the general popula-
tion, although the rate in pregnancy is unknown [55].
While rare, adverse reactions have been reported in
almost all organ systems, including gastrointestinal, der-
matologic, hematologic, renal, and immunologic (ana-
phylaxis) [26]. Isolated cases of aplastic anaemia,
leukopenia, neutropenia, and thrombocytopenia have
been reported [56]. Early reports suggested that probe-
necid may be associated with haemolysis in individuals
with glucose-6-phosphatase dehydrogenase (G6PD) defi-
ciency [57]. However, this has not been shown to be the
case in subsequent studies [58,59]. Furthermore, recent
reviews report that probenecid is not likely to cause
haemolysis in patients with G6PD deficiency [60,61].
Probenecid has, however, been associated with immune
mediated haemolytic anaemia in several case reports
[62,63]. Nephrotic syndrome, which typically resolves on
removal of drug, has been reported in a very small num-
ber of cases, with one case progressing to death [64-68].
There has also been a single case report of fatal haepatic
necrosis [69]. Hypersensitivity reactions to probenecid in
the general population may occur in as many as 2% to
4%. The incidence of probenecid hypersensitivity is
much higher in HIV-infected patients ranging from 11%
to 25% [70]. These reactions ranged from a mild rash
that resolved with continued drug administration to
more severe reactions consisting of a diffuse rash
accompanied by constitutional symptoms, including
fever and hypotension, leading to discontinuation of the
drug [71-73]. There has been a single case report of
anaphylactoid reaction after a single oral dose of probe-
necid [74].
Sulphadoxine-pyrimethamine (SP)
Despite a long list of potentially severe side effects asso-
ciated with sulphonamides, the dose of SP used for
IPTp is generally well tolerated [50,51]. Bone marrow
suppression including agranulocytosis, aplastic anaemia,
megaloblastic anaemia, thrombocytopenia, leukopenia,
haemolytic anaemia, and eosinophilia may be seen. Hae-
matologic adverse events are related to folic acid antag-
onism, and can generally be reversed with folinic acid
[51]. Mild adverse reactions, such as nausea, vomiting,
rash, pruritus, and fatigue have been reported in a small
proportion (1-2%) of patients following a single dose of
SP [1,75-77]. Parise et al. reported an increased inci-
dence of adverse events in women with HIV, but this
was not confirmed in a study by Filler et al. [75,76].
Severe adverse events are rare [1]. Cutaneous hypersen-
sitivity reactions (i.e. Stevens-Johnson syndrome and
toxic epidermal necrolysis) are the most common severe
adverse events. In studies of travellers taking weekly SP
for malaria prophylaxis, the rate of cutaneous hypersen-
sitivity reactions has been reported to be approximately
one per 5,000-8,000, with one fatality per 11,000-25,000
[78-80]. The crude rate of cutaneous hypersensitivity
reaction was reported to be approximately 1.2 per
100,000 exposures to SP in passive surveillance data
from 22 health facilities in Blantyre, Malawi [81]. In that
study, the rate of cutaneous hypersensitivity in HIV-
infected individuals was approximately four times the
crude rate, at 4.9 cases per 100,000 [81]. In a study
comparing IPTp with standard SP to SP plus azithromy-
cin, Luntamo et al. reported 14 maternal severe adverse
events, including one maternal death, among 1,320
women (1%). However, the majority of these were con-
sidered to be unrelated to the study drugs [82]. It is
unclear whether any of the reported adverse events were
severe cutaneous reactions. In a systematic review of
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deaths among 11,379 doses of SP given to 4,911 women;
nine of these occurred in women receiving placebo [1].
Only one of these deaths was reported to be due to a
severe cutaneous hypersensitivity reaction, and it
occurred in an HIV-positive woman three weeks after
t h ed o s eo fS P[ 1 , 7 7 ] .Am o r ec o m p r e h e n s i v er e v i e wo f
cutaneous hypersensitivity reactions was conducted by
Peters et al. [51]. Other, less common, severe reactions
that have been seen with SP use include liver toxicity
(e.g. cholestatic hepatotoxicity and fulminant hepatic
necrosis), fever, and respiratory problems such as hyper-
sensitivity pneumonitis [51]. Patients with G6PD defi-
ciency can safely receive SP-IPTp or malaria treatment
with SP [51,83].
Pregnancy
Probenecid
Probenecid is known to cross the placental barrier and
appears in cord blood [48]. There are limited data on
the use of probenecid in pregnancy, with approximately
460 cases described in the literature (Table 1). In most
of these cases, no data are provided on the outcome of
pregnancy. Of the few studies that describe foetal out-
comes, none shows a statistically significant increase in
foetal adverse events in infants exposed to probenecid
compared to controls [84], although the small sample
size of most of these studies is a major limitation to
effectively evaluating infant outcomes. Due to the pau-
city of data, the US Food and Drug Administration clas-
sifies probenecid as Pregnancy Category B. However, the
data available do not suggest any evidence of teratogenic
effects of probenecid when used in pregnancy [48,55].
Sulphadoxine-pyrimethamine
SP is classified by the US Food and Drug Administration
as belonging to Pregnancy Category C. Pyrimethamine is
teratogenic at doses well above the standard human
dose in rats, hamsters and miniature pigs; effects includ-
ing foetal re-absorption, cleft palate, bradygnathia, oligo-
dactyly, and microphthalmia have been seen [50].
Sulphadoxine is also teratogenic in rats [50]. In rabbits,
no teratogenic effects were noted at oral doses as high
as 20 mg/kg pyrimethamine plus 400 mg/kg sulphadox-
ine [50]. One large study in humans looking at the effect
of folic acid antagonists found an increased risk of mal-
formations, including cardiovascular defects, oral clefts,
and urinary tract defects, with exposure in the first tri-
mester, but not in subsequent trimesters [91]. However,
several large studies of SP-IPTp, including several ran-
domized controlled trials, have not found an association
between the use of SP and congenital anomalies [67,68].
Therefore, despite data suggesting teratogenicity in cer-
tain animal models, there is a large body of evidence
suggesting that SP-IPTp is safe for use in humans dur-
ing the second and third trimesters. Of note, probenecid
in combination with SP would potentiate the antifolate
effect of SP [36], with the potential danger of reducing
the folates available to the growing foetus. Therefore,
should this combination be adopted, careful monitoring
is suggested to ensure that the combination does not
have harmful effects [13].
Both pyrimethamine and sulphadoxine cross the placen-
tal barrier and also pass into breast milk [50]. Sulphona-
mides could theoretically increase the risk of kernicterus
in the infant if given to a pregnant woman near term, due
to the ability of sulphonamides to displace unconjugated
bilirubin from albumin [51]. However, this has not actually
been seen in clinical trials of IPTp, clinical treatment of
cases of malaria or in the treatment of congenital toxo-
plasmosis (which uses pyrimethamine, sulphadiazine and
folinic acid) [51,91].
Drug interactions
Probenecid
Probenecid is a ucosuric agent that inhibits the tubular
secretion of organic anion derivatives. These organic
anions (such penicillin and analogs), which are primarily
derivatives of carboxylic acid (DCA), are secreted in the
kidney by organic anion transporters (OATs). Probe-
neicd, which is also a DCA, interacts with these OATs,
leading to a decrease in DCA secretion [92,93]. Thus,
the mechanism of action of probenecid depends on the
inhibition of OATs, reducing the secretion of DCA.
Most of the drugs reported in the list below are organic
anion compounds that are secreted through OATs,
hence their interaction with probenecid. In the next sec-
tion, we detail specific probenecid-drug interaction.
List of drugs whose concentration or effects are increased
by probenecid
￿ Antibacterials: Penicillins, Cephalosporins, Carbape-
nems, Quinolones, Dapsone, Rifampin, Tazobactam
￿ Antivirals: Ganciclovir, Valganciclovir, Oseltama-
vir, Peramavir
￿ Antiretrovirals: Zalcitabine, Zidovudine
￿ Methotrexate
￿ Acetaminophen
￿ Non-steroidal anti-inflammatory drugs:I n d o -
methacin, Ketoprofen, Ketorolac, Naproxen,
Zomepirac
￿ Benzodiazepines: Lorazepam, Midazolam,
Nitrazepam
￿ Chlorothiazide (thiazide)
￿ Loop Diuretics: Bumetanide, Furosemide
￿ Mycophenolate
￿ Theophylline Derivatives: Dyphylline, Enprofylline
but NOT Aminophylline or Theophylline
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￿ Nitrofurantoin
￿ Apazone
￿ Entacapone
￿ Famotidine
￿ Pemetrexed
￿ Pralatrexate
￿ Sodium Phenylacetate, Sodium Benzoate
Probenecid is antagonized by both salicylates and
pyrazinamide [31]. Allopurinol decreases the serum
concentration of probenecid while probenecid
increases that of allopurinol. However, the clinical sig-
nificance of this is probably minimal [31]. Probenecid
decreases the natriuretic effect of piretanide [31]. Pro-
benecid increases the metabolism of phenprocoumon,
leading to decreased AUC [94]. Probenecid has a
nephroprotective effect when co-administered with
cidofovir, but without significantly altering plasma
blood levels [94]. It is a weak inhibitor of CYP2C19
and blocks the renal transport of many compounds
including many classes of antibiotics, antivirals, and
NSAIDs leading to an increase in their mean plasma
elimination half-life that can lead to increased plasma
concentrations [31]. In some cases, this may increase
the potential for toxicity.
Sulphadoxine-pyrimethamine
Neither sulphadoxine nor pyrimethine, nor their pri-
mary metabolites, are DCA [95,96], thus the mechan-
isms of secretion of these two drugs are not likely to
involve OATs. Therefore, their pharmacokinetics would
not be affected by probenecid. In support of this
hypothesis, the clinical evaluation of probenecid with SP
did not indicate any increase in sulfadoxine or pyri-
methamine toxicity [19]. However, further investigations
need to be carried out to establish the pharmacokinetics,
safety, and efficacy of probenecid + SP, before this com-
bination could be used routinely for IPTp.
Table 1 Reports of probenecid use during pregnancy
Author Study N Treatment Timing of Treatment SAEs Infant Outcome
Cavenee
et al. [84]
Treatment of
gonorrhoea in
pregnancy
123 Amoxicillin 3 gm +
probenecid 1 gm
64 patients (25%)
treated in 1st
trimester of
pregnancy
None, one woman
reported vomiting
several hours after
taking the drug
71 infants were evaluated, 14 treated < 14
week, 1 major malformation (7%), 4 minor
malformations (29%); 57 > 14 week, 0
major and 10 minor malformations (18%),
overall 1% major and 20% minor
malformations, not statistically different
from other groups
Adelson
et al. [85]
Treatment of
urinary tract
infections in
pregnancy
98 Ampicillin 3.5 gm +
probenecid 1 gm
Not stated 3 patients developed
candidal vulvo-
vaginitis, 3 patients
developed diarrhoea
Not stated
Brown et
al. [86]
Renal
clearance of
oestrogen in
pregnancy
9 Probenecid 2.5 gm Last 6 weeks of
pregnancy
None reported No foetal deaths or stillbirths
Lee et al.
[87]
Gout and
pregnancy
1 Probenecid 1 gm to
3 gm daily
throughout
pregnancy
Throughout
pregnancy
Anaemia thought
related to renal
disease
Healthy infant
Weingold
et al. [88]
Gout and
pregnancy
1 Colchicine and
probenecid
Throughout 1st
pregnancy and for
the first 14 weeks of
2
nd pregnancy
Mild anaemia 1st pregnancy: infant died on DOL4 due to
hyaline membrane disease
2
nd pregnancy: healthy infant
Goodrich
[55]
Gonorrhoea
and
pregnancy
163 Penicillin G 4.8 × 10
6
U (n = 158) or
ampicillin (n = 5) +
probenecid 1 gm
Not stated None reported Not stated
Schackis
[89]
Hype-
ruricemia and
pre-eclampsia
20* Probenecid 250 mg
twice daily for 7 days
26-32 weeks
gestation
No side-effects to
probenecid were
recorded
There were 3 intrauterine foetal deaths: 1
from an abruptio placenta (> 1 kg) in the
probenecid group and 2 from suspected
placental insufficiency (both < 1 kg): 1
each in the probenecid and placebo
group.
Czaczkes
et al. [90]
Pre-eclampsia,
eclampsia
18† Probenecid 0.5 gm 3
times daily for 5-6
days
Not stated None reported Not stated
*20 women treated and an additional 20 untreated controls
†15 women with pre-eclampsia + 3 pregnant controls without pre-eclampsia
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folates (i.e. trimethoprim), sulphonamides, or other
agents associated with myelosuppression, as this can
increase the risk of bone marrow suppression (Table 2).
The concurrent use of gold salts and anti-malarial agents
is also contraindicated due to an increased risk of blood
dyscrasias. Sulphadoxine decreases the serum concentra-
tion of cyclosporine while enhancing its nephrotoxic
effect. Potassium P-aminobenzoate and its derivatives
(Procaine, benzocaine, and tetracaine) can decrease the
therapeutic effect of sulphadoxine, while folate deriva-
tives can decrease the therapeutic effect of pyrimetha-
mine. The concomitant administration of antacids or
absorbent anti-diarrhoeals may significantly reduce the
bioavailability of pyrimethamine by reducing its absorp-
tion. Pyrimethamine inhibits CYP2C9 and CYP 2D6, and
may therefore interact with other compounds, which are
metabolized via these pathways (Table 3).
SP-IPTp works both through clearance of existing
asymptomatic infections as well as prophylactically by
preventing new infections [1]. The prophylactic effect of
SP is believed to be of primary importance [1]. Due to
the long half-life of SP, its parasitocidal drug levels are
sustained for weeks in the case of sensitive parasites,
providing a prolonged period of prophylaxis. As parasite
resistance to SP increases, the period of prophylactic
efficacy becomes shorter [21]. Even if probenecid can
increase the concentration of SP, given the very short
half-life of probenecid (less than 20 h) compared to SP
(approximately 100 h), this effect is unlikely to be sus-
tained. Therefore, while the addition of a single dose of
probenecid to SP may be useful for treatment, it is
unclear to what extent it will provide a prolonged period
of prophylaxis in the context of IPTp. Multiple doses of
probenecid may be needed to provide a sustained bene-
fit of SP-IPTp. However, a multiple-dose regimen would
be less ideal as compliance with such a regimen is likely
to be low.
Conclusions
T h ea n t i f o l a t eS Pi sw i d e l yu s e df o rI P T p ;i ti st h eo n l y
drug currently recommended for IPTp by WHO and
has been adopted as national policy in 37 countries
worldwide, 33 of which are in the sub-Saharan region
Table 2 Drugs that interact with sulphadoxine
Drug Effect of Interaction
Phenytoin Serum hydantoin levels and risk of toxicity may be increased due to inhibition of hepatic metabolism by
sulphadoxine
Sulphonylureas (Glimepiride,
Glyburide)
The hypoglycemic potential of the sulphonylureas may be increased; the mechanism of this interaction is
unknown.
Vitamin K antagonists (Coumadin,
anisindione)
Co-administration with a sulphonamide may increase the plasma concentrations and hypoprothrombinemic
effects of coumarin anticoagulants
Gold salts Increase the risk of blood dyscrasias
Cyclosporine Sulphadoxine decreases the serum concentration of cyclosporine while enhancing its nephrotoxic effect
Table 3 Drugs that interact with pyrimethamine
Drug Effect of Interaction
Gold salts Increased risk of blood dyscrasias
Methotrexate Increased risk of bone marrow suppression
Dapsone Folate antagonists may increase the likelihood of adverse hematologic reactions (e.g., agranulocytosis, anaemia)
Carvedilol Possible for increased serum concentration of the S-carvedilol enantiomer
Phenothiazines Anti-malarial agents may increase the serum concentration
Fesoterodine Serum concentrations of the active metabolite may be increased
Nebivolol Serum concentration may be increased
Zidovudine, abacavir,
lamivudine
Increased risk of bone marrow suppression
Tamoxifen Metabolism of Tamoxifen to the active metabolites may be decreased
Lorazepam Increases risk of elevated liver function tests
Codeine CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine, diminishing
its therapeutic effect
Tramadol CYP2D6 inhibitors may prevent the metabolic conversion to the active metabolite, diminishing its therapeutic effect
Antacids Reduce the absorption of pyrimethamine (decreased bioavailability)
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Page 7 of 10[97,98]. However, resistance of malaria parasites to SP
has been increasing, and there is accumulating evidence
from eastern Africa that the efficacy of SP-IPTp is
declining. Therefore, new drugs and strategies are
urgently needed. As malaria transmission declines, the
risk associated with administering a drug to all pregnant
women will no longer outweigh the potential benefit
associated with preventing malaria, and it is likely that
IPTp will be abandoned. In the interim, in vitro and in
vivo data suggest that combining probenecid with SP
significantly increases the efficacy of SP, and might
therefore be a useful strategy in HIV-uninfected women
until new drugs for IPTp are evaluated and deployed
[13-16], although this combination may not be suffi-
ciently efficacious in areas with a high degree of resis-
tance. Although probenecid has been in use for many
decades, very few data exist on its use in pregnancy;
however, the available data suggests that it is safe. Prior
to recommending this combination for widespread use,
additional information is needed on its safety and phar-
macokinetics in pregnancy, and given the difference in
the half-lives of SP and probenecid, data are needed to
determine the optimal dosing schedule. In addition, stu-
dies are needed to determine whether the increased
dose of SP achieved by this combination improves the
efficacy against partially resistant parasites. Mathemati-
cal modelling may be able to assist in this determina-
tion. Overall, available data on efficacy, safety and cost
for these drugs necessitates further research into their
combination for use in IPTp [48,55].
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